BACKGROUND:Pediatric fixed-dose combinations (FDCs) are needed to facilitate antiretroviral therapy in children. We evaluated the relative bioavailability, safety, and therapeutic adequacy of a novel chewable pediatric FDC tablet of stavudine (7 mg), lamivudine (30 mg), and nevirapine (50 mg), referred to as GPO-VIR S7, and compared it with the individual original brand-name liquid formulations in human immunodeficiency virus-infected Thai children. METHODS: The International Maternal Pediatric Adolescent AIDS Clinical Trials group (IMPAACT) P1056 study was a phase I/II, 2-arm, randomized, open-label, multidose pharmacokinetic cross-over study. Children ≥6 to ≤30 kg receiving nevirapine-based HAART for at least 4 weeks were randomized to receive GPO-VIR S7 chewable tablets or the equivalent liquid formulations. Children were stratified by weight and dosing was weight-based. Intensive 12-hour blood sampling was performed on day 28, and subjects then crossed-over to the alternate formulation at equal doses with identical 12-hour sampling on day 56. Pharmacokinetic indices were determined by noncompartmental analysis. RESULTS:Thirty-four children completed the study. While taking Government Pharmaceutical Organization (GPO)-VIR S7 the geometric mean (90% CI) area under the curve was 1.54 μg·hr/mL (1.42-1.67) for stavudine, 6.39 (5.82-7.00) for lamivudine, and 74.06 (65.62-83.60) for nevirapine. Nevirapine drug exposure for GPO-VIR S7 was therapeutically adequate. Geometric mean area under the curve ratios (90% CI) of GPO-VIR S7/liquid formulation for stavudine, lamivudine, and nevirapine were 0.97 (0.92-1.02), 1.41 (1.30-1.53), and 1.08 (1.04-1.13), respectively. No serious drug-related toxicity was reported. CONCLUSIONS: The chewable FDC was safe and provided therapeutically adequate plasma drug exposures in human immunodeficiency virus-infected children. Substituting the FDC for liquid formulations can simplify antiretroviral therapy.
RCT Entities:
BACKGROUND: Pediatric fixed-dose combinations (FDCs) are needed to facilitate antiretroviral therapy in children. We evaluated the relative bioavailability, safety, and therapeutic adequacy of a novel chewable pediatric FDC tablet of stavudine (7 mg), lamivudine (30 mg), and nevirapine (50 mg), referred to as GPO-VIR S7, and compared it with the individual original brand-name liquid formulations in humanimmunodeficiency virus-infected Thai children. METHODS: The International Maternal Pediatric Adolescent AIDS Clinical Trials group (IMPAACT) P1056 study was a phase I/II, 2-arm, randomized, open-label, multidose pharmacokinetic cross-over study. Children ≥6 to ≤30 kg receiving nevirapine-based HAART for at least 4 weeks were randomized to receive GPO-VIR S7 chewable tablets or the equivalent liquid formulations. Children were stratified by weight and dosing was weight-based. Intensive 12-hour blood sampling was performed on day 28, and subjects then crossed-over to the alternate formulation at equal doses with identical 12-hour sampling on day 56. Pharmacokinetic indices were determined by noncompartmental analysis. RESULTS: Thirty-four children completed the study. While taking Government Pharmaceutical Organization (GPO)-VIR S7 the geometric mean (90% CI) area under the curve was 1.54 μg·hr/mL (1.42-1.67) for stavudine, 6.39 (5.82-7.00) for lamivudine, and 74.06 (65.62-83.60) for nevirapine. Nevirapine drug exposure for GPO-VIR S7 was therapeutically adequate. Geometric mean area under the curve ratios (90% CI) of GPO-VIR S7/liquid formulation for stavudine, lamivudine, and nevirapine were 0.97 (0.92-1.02), 1.41 (1.30-1.53), and 1.08 (1.04-1.13), respectively. No serious drug-related toxicity was reported. CONCLUSIONS: The chewable FDC was safe and provided therapeutically adequate plasma drug exposures in humanimmunodeficiency virus-infectedchildren. Substituting the FDC for liquid formulations can simplify antiretroviral therapy.
Authors: Heather E Vezina; Keith Henry; G D Ravindran; Anura V Kurpad; Tony D S Raj; Kathy Fox; Dennis Weller; Richard C Brundage; Winston Cavert; Henry H Balfour Journal: J Acquir Immune Defic Syndr Date: 2006-02-01 Impact factor: 3.731
Authors: Mina C Hosseinipour; Amanda H Corbett; Cecelia Kanyama; Idah Mshali; Severiano Phakati; Nazer L Rezk; Charles van der Horst; Angela D M Kashuba Journal: AIDS Date: 2007-01-02 Impact factor: 4.177
Authors: Rafaëlla F A L'homme; Desiré Kabamba; Fiona M Ewings; Veronica Mulenga; Chipepo Kankasa; Margaret J Thomason; A Sarah Walker; Chifumbe Chintu; David M Burger; Diana M Gibb Journal: AIDS Date: 2008-03-12 Impact factor: 4.177
Authors: D M Burger; G Verweel; N Rakhmanina; C P W G M Verwey-Van Wissen; C J L La Porte; A S Bergshoeff; H Lyall; N G Hartwig; H Green; S Soldin; D M Gibb; R de Groot Journal: Clin Pharmacol Ther Date: 2007-02-28 Impact factor: 6.875
Authors: Esther J H Janssen; Diane E T Bastiaans; Pyry A J Välitalo; Annemarie M C van Rossum; Evelyne Jacqz-Aigrain; Hermione Lyall; Catherijne A J Knibbe; David M Burger Journal: Br J Clin Pharmacol Date: 2017-02-14 Impact factor: 4.335
Authors: Adriana H Tremoulet; Mina Nikanjam; Tim R Cressey; Kulkanya Chokephaibulkit; Ross McKinney; Mark Mirochnick; Edmund V Capparelli Journal: J Clin Pharmacol Date: 2011-12-16 Impact factor: 3.126
Authors: Mina Nikanjam; Desiré Kabamba; Tim R Cressey; David Burger; Francesca T Aweeka; Edward P Acosta; Stephen A Spector; Edmund V Capparelli Journal: Antimicrob Agents Chemother Date: 2012-08-06 Impact factor: 5.191
Authors: Ralf Weigel; Caryl Feldacker; Hannock Tweya; Chimwemwe Gondwe; Jane Chiwoko; Joe Gumulira; Mike Kalulu; Sam Phiri Journal: J Int AIDS Soc Date: 2012 Impact factor: 5.396
Authors: Kathleen Doherty; Shaffiq Essajee; Martina Penazzato; Charles Holmes; Stephen Resch; Andrea Ciaranello Journal: BMC Health Serv Res Date: 2014-05-02 Impact factor: 2.655